Karyopharm Therapeutics, Inc.
(NASDAQ : KPTI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.60%163.540.7%$1305.95m
LLYEli Lilly & Co. -1.93%323.651.1%$1056.02m
ABBVAbbVie, Inc. -5.84%134.381.9%$793.06m
PFEPfizer Inc. -0.75%43.830.9%$778.51m
BMYBristol-Myers Squibb Co. -0.82%71.121.0%$763.08m
MRKMerck & Co., Inc. -0.52%86.190.7%$687.90m
AZNAstraZeneca Plc -0.13%54.841.0%$411.81m
NVSNovartis AG -0.73%76.010.2%$216.26m
GSKGSK Plc 0.31%29.450.3%$214.53m
ALNYAlnylam Pharmaceuticals, Inc. -4.41%200.168.2%$210.64m
GBTGlobal Blood Therapeutics, Inc. 0.04%68.105.4%$190.73m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.21%151.220.0%$178.64m
IDXXIDEXX Laboratories, Inc. -1.81%325.803.9%$175.84m
HZNPHorizon Therapeutics Plc -1.28%61.895.4%$160.55m
NVONovo Nordisk A/S -0.74%99.650.1%$140.44m

Company Profile

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.